Nasdaq

Indivior Announces FDA Grants Priority Review For SUBLOCADE Prior Approval Supplement

(RTTNews) - Indivior Plc.(INDV) announced that the U.S. Food and Drug Administration has granted Priority Review designation for the Prior Approval Supplement of SUBLOCADE (buprenorphine ...
Seeking Alpha

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
WDAF-TV

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data ...

Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...
Seeking Alpha

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use ...

Evidence demonstrates that SUBLOCADE supports long-term recovery from opioid use disorder (OUD) and is effective and safe. Publications highlight the importance of overcoming access barriers to ...

Indivior (INDV) Q4 2025 Earnings Call Transcript

Thanks, Jason, good morning and thank you for joining us on today's call to review our fourth quarter and full year 2025 results. Last July, we rolled out the Indivior Action Agenda to maximize the ...